Among these therapies, immune checkpoint inhibitors including cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1) have been approved for the treatment of a variety of tumours [5]. The gene discussed is PDCD1; the disease is neoplasm.